630G

MEDTRONIC ANNOUNCES HEALTH CANADA LICENCE OF THE MINIMED™ 630G SYSTEM WITH NEW USER-FRIENDLY INSULIN PUMP DESIGN AND SMARTGUARD™ TECHNOLOGY

BRAMPTON, Canada – Oct. 20, 2016 – Medtronic Canada, a subsidiary of Medtronic plc (NYSE:MDT), announced today the Health Canada licence of its MiniMed™ 630G system with SmartGuard™ technology for people with diabetes mellitus. The MiniMed 630G system features a new insulin pump hardware platform and a new user-friendly design that combines personalized diabetes management with industry-leading clinical performance. The MiniMed 630G system is the newest offering of the MiniMed family-the #1 selling pump brand in Canada†.

After interviewing more than 1,000 people with diabetes and testing user-experience, the enhanced features of the MiniMed 630G system were finalized to take into account what matters most to those with diabetes. This collaborative process with the patient community resulted in a new, user-friendly pump design that is waterproof[i] and features a high-definition, full-colour screen that supports easy navigation and enables increased customization with more intuitive menus.

 

 “We are excited to announce the launch of the MiniMed 630G system for Canadians living with diabetes.  This latest innovation is a step towards Medtronic’s vision of transforming diabetes care and our commitment to providing improved outcomes and an improved user experience for our customers,” said Laura Cameron, Director of Diabetes & Consumer Care in Canada.

The MiniMed 630G system combines its proprietary SmartGuard technology with a brand new user-friendly design. The new pump platform fully integrates continuous glucose monitoring (CGM) and SmartGuard technology, which is designed to trigger an alarm when the CGM sensor glucose level reaches a preset low limit and suspends insulin delivery if the user is unresponsive to the alarm. SmartGuard technology is the only feature available in Canada that takes action against lows[i] and is the only system proven to reduce the frequency of nighttime low episodes[ii] by a third.2,[iii]

Data from the ASPIRE In-Home Study published in the New England Journal of Medicine2 demonstrated that SmartGuard technology not only reduces the number of low events2 per week by 30 percent but also shortens the length/intensity of those events at night by 37.5 % without increasing A1C (a measure of average blood sugar levels over three months).4 These results were validated with real-world data from the company's CareLink™ Personal software that included an analysis of 581,822 days of data in Canada, which demonstrated SmartGuard technology users experience about half as many nighttime lows3 than those using a pump and sensor alone.[iv] MiniMed integrated insulin pump technology with CGM has also been proven to provide better glucose control than multiple daily injections without increasing hypoglycemia (low blood sugar).[v]

The MiniMed 630G system with SmartGuard technology will be commercially available in Canada in early 2017.

About the Diabetes Group at Medtronic (www.medtronicdiabetes.ca)

Medtronic is working together with the global community to change the way people manage diabetes. The company aims to help transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic

Medtronic Canada (www.medtronic.ca), headquartered in Brampton, Ontario is a subsidiary of Medtronic plc, which is among the world’s largest medical technology, services and solutions companies — alleviating pain, restoring health and extending life for millions of people around the world. Medtronic is proud to employ over 1,600 people in Canada, serving physicians, hospitals and patients across the country. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 MiniMed 630G is waterproof in up to 3.6 meters (12 feet) of water for up to 24 hours at the time of manufacture; Guardian Link Transmitter is waterproof in up to 2.4 meters (8 feet) of water for up to 30 minutes. See IFU for additional information on the waterproof feature.

2 Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369(3):224-232.

3Measured in sensor glucose values.

3 Based upon limited sample size and duration of ASPIRE In-Home study.

5 Data from only the voluntary CareLink® Personal Uploads from the Veo system OUS available from May 1, 2011 to October 20, 2015 evaluated.

6 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320.

†Based on sales. Data on file.